Aptose to Present at Upcoming Investor Conferences in October 2018
SAN DIEGO, Calif. and TORONTO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that William G. Rice, Chairman, Ph.D., President and Chief Executive Officer, and Gregory K. Chow, Senior Vice President and Chief Financial Officer, will participate at the following upcoming conferences:
• 2018 Cantor Fitzgerald Global Healthcare Conference Date: Tuesday, October 2, 2018 Time: 8:00 a.m. EDT Format: Company Presentation Location: Intercontinental New York Barclay Hotel, New York City Live webcast: Cantor Fitzgerald Conference Webcast Link • Leerink Partners Roundtable Series: Rare Disease & Oncology Date: Wednesday, October 3, 2018 Time: 2:00 p.m. EDT Format: Fireside Chat Location: Lotte New York Palace Hotel, New York City Live webcast: Leerink Partners Conference Webcast Link • 18th Annual Biotech in Europe Forum Date: Friday, October 5, 2018 Location: Centre Congress, Basel, Switzerland -- 9:45 a.m. CEST – Company Presentation -- 12:10 p.m. CEST – Oncology II –Advanced Therapeutics Panel
The live webcasts can also be accessed through the Aptose website at www.aptose.com and will be archived shortly after the live event and available for 90 days.
Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The company’s small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. APTO-253, the only clinical stage agent that directly targets the MYC oncogene and inhibits its expression, is in a Phase 1b clinical trial for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or high risk MDS. CG-806 is an oral, first-in-class pan-FLT3/pan-BTK multi-cluster kinase inhibitor expected to reach IND submission by the end of 2018 and is planned for development to treat AML and certain B cell malignancies. For further information, please visit www.aptose.com.
For further information, please contact:
Aptose Biosciences Greg Chow, CFO 647-479-9828 firstname.lastname@example.org SMP Communications LifeSci Advisors Susan Pietropaolo Michael Wood 201-923-2049 Managing Director email@example.com 646-597-6983 firstname.lastname@example.org